Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest Financial Results

FY 2019

Fiscal Year Ended Dec 31, 2019

Latest 10-K

View Latest 10-K

Stock Information


Nasdaq: CWBR




52 week Low/High

Day Low/High

Company Overview

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring, mitochondrial peptides encoded in the mitochondrial genome, which regulate metabolism, cell death and other important biological functions, and whose activity declines with age. CohBar’s efforts focus on the development of these peptides into novel therapeutics that offer the potential to address a broad range of large population and orphan diseases. The company and its founders have discovered more than 100 mitochondrial-derived peptides which may be developed into breakthrough treatments for a number of these diseases with enormous unmet medical needs.

Q4 2019 Shareholder Presentation

Q4 2019 Shareholder Presentation



Our scientific and management teams are our backbone, providing experience and proven success.

Investor Contact Information


CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park, CA 94025
T: (650) 446-7888

Investor Relations

Jordyn Tarazi
Director, Investor Relations
T: (650) 445-4441

Transfer Agent

American Stock Transfer & Trust Company (Canada)
1066 West Hastings Street
Suite 1600
Vancouver, BC V6E 3X1